BOSTON, May 4, 2015 /PRNewswire/ -- PAREXEL International
Corporation (NASDAQ: PRXL) announced today that it will be
presenting at the UBS Healthcare Conference on Monday, May 18, 2015, in New York City.
Ingo Bank, Senior Vice President and
Chief Financial Officer will be making a presentation on PAREXEL
and discussing business developments at 11:30 a.m. ET.
A live webcast of the presentation will be available through the
"Investors" section of PAREXEL's website at www.PAREXEL.com
in the Upcoming Events portion of the main page, and a replay of
the presentation will be available on the website for 90 days after
the presentation.
About PAREXEL International
PAREXEL
International Corporation is a leading global biopharmaceutical
services organization, providing a broad range of expertise-based
contract research, consulting, medical communications, and
technology solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics, Inc. provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston,
Massachusetts, PAREXEL operates in 80 locations in 51
countries around the world, and had approximately 17,440 employees
in the third quarter. For more information about PAREXEL
International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates.
CONTACT:
Jill Baker, Corporate Vice President
of Investor Relations
+1-781-434-4118
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-international-to-present-at-ubs-healthcare-conference-300076187.html
SOURCE PAREXEL International Corporation